# US 11,077,316 B2 · Insertion devices and systems for production of emitted light internal to a medium and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,316 B2
- Document ID: US11077316B2
- Status: Granted
- Kind: B2
- Application number: 16/096,174
- Filed: 2017-04-25
- Published: 2019-05-09
- Granted: 2021-08-03
- Earliest claimed: 2016-04-25
- Assignees: Immunolight, LLC
- Applicants: Immunolight, LLC
- Inventors: Frederic A. Bourke, Jr.; Harold Walder; Zakaryae Fathi; Wayne F. Beyer, Jr.
- Web page: https://patentgrep.com/patent/US11077316B2

## CPC

- A61N 5/0601: {Apparatus for use inside the body}
- A61K 31/015: carbocyclic
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61N 1/40: Applying electric fields by inductive or capacitive coupling (microwave apparatus A61N5/00); {Applying radio-frequency signals}
- A61N 5/06: using light
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61M 2205/10: with powered movement mechanisms
- A61N 1/37205: {Microstimulators, e.g. implantable through a cannula}
- A61N 5/02: using microwaves
- A61N 5/045: {specially adapted for treatment inside the body}
- A61N 5/0624: {for eliminating microbes, germs, bacteria on or in the body}
- A61N 2005/0602: {for treatment of blood vessels}
- A61N 2005/0651: {Diodes}
- A61N 2005/0656: {Chemical light sources}
- A61N 2005/0665: {Reflectors}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.

## Claims

### Claim 1

A system for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, comprising:
an emitter configured, in response to an initiation signal, to emit said wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium,
a controller which provides a control signal moderating an amount of said light being emitted in the human or animal subject, and
an x-ray breakable container holding at least one of a biotherapeutic fluid or a photoactivatable fluid, wherein upon x-ray exposure a container wall breaks releasing said at least one of a biotherapeutic fluid or a photoactivatable fluid to the medium or to the human or animal subject.

### Claim 2 (depends on 1)

The system of claim 1, wherein the emitter comprises an active device including a receiver for reception of at least one of the initiation signal and the control signal.

### Claim 3 (depends on 2)

The system of claim 2, wherein the emitter further comprises a processor which contains programmed instructions determining a schedule for administration of said wavelength of energy to the medium or internal to the human or animal subject.

### Claim 4 (depends on 2)

The system of claim 2, wherein the emitter comprises a light emitting diode or an electroluminescent device configured to emit said wavelength of energy.

### Claim 5 (depends on 2)

The system of claim 2, further comprising a fluid reservoir including a biotherapeutic fluid.

### Claim 6 (depends on 5)

The system of claim 5, further comprising at least one fluid channels for delivery of the biotherapeutic fluid to the human or animal subject.

### Claim 7 (depends on 2)

The system of claim 2, further comprising a fluid reservoir including a photoactivatable fluid.

### Claim 8 (depends on 7)

The system of claim 7, further comprising at least one fluid channel for delivery of the photoactivatable fluid to the medium or to the human or animal subject.

### Claim 9 (depends on 1)

The system of claim 1, wherein the x-ray breakable container comprises a glass including at least one of a silicate glass, an alkali glass, a sodium glass, and a phosphate glass doped with a heavy metal.

### Claim 10 (depends on 9)

The system of claim 9, wherein the heavy metal in the glass comprises at least one of Pb, Cr, and Th.

### Claim 11 (depends on 2)

The system of claim 2, wherein the emitter comprises a passive device without electrical circuitry.

### Claim 12 (depends on 11)

The system of claim 11, wherein the passive device comprises at least one of a phosphorescent or fluorescent agent.

### Claim 13 (depends on 11)

The system of claim 11, wherein the passive device comprises at least one of a sulfide, a telluride, a selenide and an oxide semiconductor and a combination thereof.

### Claim 14 (depends on 11)

The system of claim 11, wherein the passive device comprises at least one of CaWO4:Pb2+, CaWO4:W, Sr3(PO4)2:Eu2+, Ba3(PO4)2:Eu2+, Y2SiO5:Ce3+, SrMg(SiO4)2:Eu2+, BaMg2Al14O24:Eu2+, ZnSiO4::Mn2+, Y3(Al,Ga)5O12:Ce3+, BaMg2Al14O24:Mn2+, BaMgAl14O23:Mn2+, SrAl12SiO19:Mn2+, ZnAl12O19:Mn2+, CaAl12O19:Mn2+, YBO3:Tb3+, Sr4Si3O8Cl4:Eu3+, Y2O3:Eu3+, Y2SiO5:Eu3+, Y3Al5O12Eu3+, CaSiO3:Mn2+, YVO4:Eu3+.

### Claim 15 (depends on 11)

The system of claim 11, wherein the passive device comprises a plasmonics agent comprising a dielectric-metal composite; or a plasmonics agent comprising a plurality of differently sized metal particles disposed in vicinity of each other as a composite plasmonics agent.

### Claim 16 (depends on 11)

The system of claim 11, wherein the passive device comprises at least one of Y2O3; ZnS; ZnSe; MgS; CaS; Mn, Er ZnSe; Mn, Er MgS; Mn, Er CaS; Mn, Er ZnS; Mn, Yb ZnSe; Mn, Yb MgS; Mn, Yb CaS; Mn, Yb ZnS:Tb3+, Er3+; ZnS:Tb3+; Y2O3:Tb3+; Y2O3:Tb3+, Er3+; ZnS:Mn2+; ZnS:Mn, Er3+; CaWO4, YaTO4, YaTO4:Nb, BaSO4:Eu, La2O2S:Tb, BaSi2O5:Pb, NaI(Tl), CsI(Tl), CsI(Na), CsI(pure), CsF, KI(Tl), LiI(Eu), BaF2, CaF, CaF2(Eu), ZnS(Ag), CaWO4, CdWO4, YAG(Ce) (Y3Al5O12(Ce)), BGO bismuth germanate, GSO gadolinium oxyorthosilicate, LSO lutetium oxyorthosilicate, LaCl3(Ce), and LaBr3(Ce).

### Claim 17 (depends on 1)

The system of claim 1, further comprising: a mechanism to administer to a subject at least one activatable pharmaceutical agent that is capable of producing a predetermined cellular change when activated by said wavelength of energy to treat a cell proliferation related disorder.

### Claim 18 (depends on 17)

The system of claim 17, wherein the cell proliferation disorder is at least one member selected from the group consisting of cancer, bacterial infection, viral infection, immune rejection response, autoimmune disorders, aplastic conditions, and combinations thereof.

### Claim 19 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent is selected from psoralens, pyrene cholesteryloleate, acridine, porphyrin, fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metal complexes of bleomycin, transition metal complexes of deglycobleomycin organoplatinum complexes, alloxazines, vitamin Ks, vitamin L, vitamin metabolites, vitamin precursors, naphthoquinones, naphthalenes, naphthols and derivatives thereof having planar molecular conformations, porphorinporphyrins, dyes and phenothiazine derivatives, coumarins, quinolones, quinones, and anthroquinones.

### Claim 20 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent is a psoralen, a coumarin, a porphyrin or a derivative thereof.

### Claim 21 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent is 8-MOP, TMP, or AMT.

### Claim 22 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent is one selected from 7,8-dimethyl-10-ribityl, isoalloxazine, 7,8,10-trimethylisoalloxazine, 7,8-dimethylalloxazine, isoalloxazine-adenine dinucleotide, alloxazine mononucleotide, aluminum (III) phthalocyanine tetrasulonate, hematophorphyrin, and phthadocyanine.

### Claim 23 (depends on 17)

The system of claim 17, wherein the predetermined cellular change is apoptosis in a target cell.

### Claim 24 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent causes an auto-vaccine effect in the subject that reacts with a target cell.

### Claim 25 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent is a DNA intercalator or a halogenated derivative thereof.

### Claim 26 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent upon activation binds to DNA associated with the cell proliferation related disorder.

### Claim 27 (depends on 17)

The system of claim 17, wherein the at least one activatable pharmaceutical agent intercalates DNA associated with the cell proliferation related disorder and upon activation binds to the DNA.

### Claim 28 (depends on 1)

A method for treating a condition, disorder, or disease, comprising:
generating an energy in-situ in a subject in need thereof, by way of the system of claim 1,
whereby the energy generated in-situ either (a) directly effects a change in the subject thus treating the condition, disorder, or disease, or (b) activates an activatable pharmaceutical agent which has been administered prior to or simultaneously with generating the energy in-situ, whereby upon activation the activated activatable pharmaceutical agent effects a change thereby treating the condition, disorder, or disease.